# Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT

> **NCT01968239** · PHASE2 · COMPLETED · sponsor: **University of Leipzig** · enrollment: 27 (actual)

## Conditions studied

- Branch Retinal Vein Occlusion

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT01968239
- **Lead sponsor:** University of Leipzig
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2016-06-17
- **Final completion:** 2016-12-20
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2018-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01968239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01968239, "Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01968239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*